Get up to date on: A clinical understanding of glucagon-like-peptide-1 (GLP-1) agonists.
Date
01 Oct 2024
Author/Presenter
Share
Table of Contents
Diabetes is a worldwide epidemic. By 2050, it is projected that the number of people living with diabetes will more than double, reaching 1.3 billion globally.1 Type 2 Diabetes Mellitus (T2DM) is a complex metabolic disorder that significantly reduces quality of life and leads to serious health complications.2 Due to the increasing prevalence and associated complications of the disease, the need for effective treatment strategies is critical.
Key highlights
- Diabetes is expected to affect 1.3 billion people by 2050.
- Semaglutide (Ozempic) is approved for T2DM, however it is also used off-label for weight loss.
- Semaglutide enhances insulin sensitivity, reduces appetite, and delays gastric emptying.
- Semaglutide may lower cardiovascular risks, including heart attacks and strokes.
- Use of semaglutide may promote muscle loss and nutrient deficiencies; monitoring protein, vitamins (B12), and minerals (zinc) is essential.